APA (7th ed.) Citation

S, K., J, D., K, N., JA, D., C, M., AF, v. d. K., . . . AP, K. (2022). Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): Primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial. The Lancet. Haematology, 9(3), e190. https://doi.org/10.1016/S2352-3026(22)00034-5

Chicago Style (17th ed.) Citation

S, Kersting, et al. "Venetoclax Consolidation After Fixed-duration Venetoclax Plus Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukaemia (HOVON 139/GiVe): Primary Endpoint Analysis of a Multicentre, Open-label, Randomised, Parallel-group, Phase 2 Trial." The Lancet. Haematology 9, no. 3 (2022): e190. https://doi.org/10.1016/S2352-3026(22)00034-5.

MLA (9th ed.) Citation

S, Kersting, et al. "Venetoclax Consolidation After Fixed-duration Venetoclax Plus Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukaemia (HOVON 139/GiVe): Primary Endpoint Analysis of a Multicentre, Open-label, Randomised, Parallel-group, Phase 2 Trial." The Lancet. Haematology, vol. 9, no. 3, 2022, p. e190, https://doi.org/10.1016/S2352-3026(22)00034-5.